Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Charles River Laboratories stock
Learn how to easily invest in Charles River Laboratories stock.
Charles River Laboratories is a diagnostics & research business based in the US. Charles River Laboratories shares (CRL) are listed on the NYSE and all prices are listed in US Dollars. Charles River Laboratories employs 18,600 staff and has a trailing 12-month revenue of around $3.7 billion.
How to buy shares in Charles River Laboratories
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CRL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Charles River Laboratories stock price (NYSE: CRL)Use our graph to track the performance of CRL stocks over time.
Charles River Laboratories shares at a glance
|Latest market close||$187.51|
|52-week range||$182.02 - $449.34|
|50-day moving average||$217.58|
|200-day moving average||$266.78|
|Wall St. target price||$272.67|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$8.73|
Buy Charles River Laboratories shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Charles River Laboratories stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Charles River Laboratories price performance over time
|1 week (2022-09-16)||N/A|
|1 month (2022-08-24)||-10.60%|
|3 months (2022-06-27)||-16.84%|
|6 months (2022-03-25)||-32.82%|
|1 year (2021-09-27)||-56.64%|
|2 years (2020-09-25)||-13.50%|
|3 years (2019-09-27)||41.39%|
|5 years (2017-09-27)||75.19%|
Is Charles River Laboratories stock undervalued or overvalued?
Valuing Charles River Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Charles River Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Charles River Laboratories's P/E ratio
Charles River Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Charles River Laboratories shares trade at around 21x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Charles River Laboratories's PEG ratio
Charles River Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.95. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Charles River Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Charles River Laboratories's EBITDA
Charles River Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $985.1 million.
The EBITDA is a measure of a Charles River Laboratories's overall financial performance and is widely used to measure a its profitability.
Charles River Laboratories financials
|Revenue TTM||$3.7 billion|
|Operating margin TTM||18.91%|
|Gross profit TTM||$1.3 billion|
|Return on assets TTM||6.12%|
|Return on equity TTM||17.87%|
|Market capitalisation||$9.5 billion|
TTM: trailing 12 months
Charles River Laboratories share dividends
We're not expecting Charles River Laboratories to pay a dividend over the next 12 months.
Charles River Laboratories share price volatility
Over the last 12 months, Charles River Laboratories's shares have ranged in value from as little as $182.02 up to $449.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Charles River Laboratories's is 1.3444. This would suggest that Charles River Laboratories's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Charles River Laboratories overview
Charles River Laboratories International, Inc. , a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products.
Charles River Laboratories in the news
Charles River (CRL) Gains From Growing Demand Amid Macro Woes
10 Stocks to Buy in 2022 According to John Rogers’ Ariel Investments
Charles River (CRL) to Support Cure AP-4's Clinical Trials
Frequently asked questionsWhat percentage of Charles River Laboratories is owned by insiders or institutions?
Currently 1.006% of Charles River Laboratories shares are held by insiders and 97.541% by institutions. How many people work for Charles River Laboratories?
Latest data suggests 18,600 work at Charles River Laboratories. When does the fiscal year end for Charles River Laboratories?
Charles River Laboratories's fiscal year ends in December. Where is Charles River Laboratories based?
Charles River Laboratories's address is: 251 Ballardvale Street, Wilmington, MA, United States, 01887 What is Charles River Laboratories's ISIN number?
Charles River Laboratories's international securities identification number is: US1598641074 What is Charles River Laboratories's CUSIP number?
Charles River Laboratories's Committee on Uniform Securities Identification Procedures number is: 159864107
More guides on Finder
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
Ask an Expert